Back to Journals » Journal of Multidisciplinary Healthcare » Volume 18
Integrating Bibliometrics and Bioinformatics to Map Knowledge Structure and Trend Synthesis in Rheumatoid Arthritis and Bone Erosion (2015–2024)
Authors Li J
, Bian Y, Han Y
, Lan M, Sun W, Wang J
Received 22 July 2025
Accepted for publication 7 November 2025
Published 20 November 2025 Volume 2025:18 Pages 7593—7608
DOI https://doi.org/10.2147/JMDH.S555600
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr David C. Mohr
Jie Li,1 Yuting Bian,2 Yuxin Han,2 Meiqi Lan,2 Wenjun Sun,1 Jianming Wang3,4
1Encephalopathy Department, Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 2Graduate School, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 3Department of TCM Rheumatology, China-Japan Friendship Hospital, Beijing, People’s Republic of China; 4Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, China-Japan Friendship Hospital, Beijing, People’s Republic of China
Correspondence: Wenjun Sun, Email [email protected] Jianming Wang, Email [email protected]
Objective: To comprehensively analyze the international trends and dynamics in rheumatoid arthritis and bone erosion research over the past 10 years, identifying research hotspots and challenges to provide references for future research directions and therapeutic strategies.
Methods: A bibliometric analysis was conducted by retrieving relevant literature published between 2015 and 2024 from the Web of Science (WoS) database. A further bibliometric analysis and visualization of the relevant literature was conducted using CiteSpace, VOSviewer, Scimago Graphica, and Excel. Further, disease-related targets were retrieved from Genecards using “rheumatoid arthritis” and “bone erosion” as keywords, followed by PPI network analysis to identify core targets and KEGG pathway enrichment analysis to elucidate key signaling pathways.
Results: A total of 1,502 publications were included through a search of the WoS database. The number of publications initially showed a gradual increase but declined sharply after 2021. China and the United States ranked as the top two contributors, with China’s proportion of publications increasing while the US proportion decreased. Cluster analysis of institutional collaboration networks revealed significant regional clustering. Arthritis Research & Therapy published the most articles in this field, while Schett, Georg ranked first in both the number of publications (34) and citations (1,436). Keyword cluster analysis indicated that research primarily focused on imaging and mechanistic exploration. PPI and KEGG analyses revealed that rheumatoid arthritis (RA) and bone erosion are closely associated with inflammatory factors and inflammation-related signaling pathways.
Conclusion: This study highlights the evolving trends in rheumatoid arthritis and bone erosion research from 2015 to 2024, demonstrating China’s growing research contributions while international collaboration remains regionally concentrated. Future efforts should emphasize interdisciplinary integration and global cooperation to advance the understanding of bone erosion mechanisms and precision medicine approaches.
Keywords: rheumatoid arthritis, bone erosion, bibliometric analysis, CiteSpace, VOSviewer
Introduction
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by synovial inflammation and progressive bone erosion, and it affects approximately 0.5–1% of the global population.1 The core pathological mechanisms of RA involve immune-mediated synovitis, subsequent pannus formation, and abnormal activation of osteoclasts that drive progressive bone erosion.2–4 As the primary cause of joint deformities, bone erosion in RA imposes substantial healthcare burdens and socioeconomic costs annually.5,6 Over the past decade, rapid advancements in molecular biology, imaging technologies, and targeted therapeutics have redefined RA bone erosion research, evolving from isolated pathological studies to dynamic cross-disciplinary research frameworks.7–10 Current research encompasses diverse domains including immune regulation, osteoclast differentiation, signaling pathway interventions, and biomaterial-based tissue repair, creating a complex and multifaceted research landscape.11–15 However, despite the rapid expansion of scientific outputs, the academic community still lacks systematic integration of shifting research priorities, knowledge network dynamics, and predictive trend modeling in RA bone erosion studies.
Bibliometrics, a quantitative research methodology grounded in big data analytics, reveals the intrinsic logic and frontier directions of disciplinary development by mining temporal-spatial distributions of academic literature, collaborative networks among authors, keyword co-occurrence patterns, and citation relationships.16 When integrated with knowledge graph visualization techniques, this approach transforms complex research themes, interdisciplinary intersections, and evolutionary trajectories into intuitive network structures, thereby offering panoramic insights into field advancement.17,18 This study employs bibliometric methods and analytical tools such as CiteSpace and VOSviewer to systematically analyze decade-long trends in scholarly output (2015–2024), characteristics of leading authors and institutional collaborations, evolution of research hotspots, and shifts in knowledge foundations within the RA bone erosion domain, using literature from the Web of Science (WoS) Collection as the dataset. A dynamic knowledge graph is constructed to visualize these findings. The results aim to provide empirical evidence for optimizing resource allocation and facilitating basic-to-clinical translation in this field, while establishing a visual reference framework to help researchers rapidly grasp the discipline’s intellectual landscape.
Materials and Methods
Data Acquisition and Search Strategies
This study conducted a comprehensive search in the WoS database on April 30, 2025, with the specific search strategy detailed in Table 1, covering a publication date range from January 1, 2015 to December 31, 2024. After preliminary screening, non-research document types such as conference abstracts, conference papers, editorial materials, book chapters, and retracted articles were excluded, and only English-language publications were retained. The final dataset was exported in plain text format for compatibility with CiteSpace and tab-delimited format tailored to the input requirements of VOSviewer, ensuring seamless integration with bibliometric analysis tools.
|
Table 1 The Search Strategies |
Bibliometric Analysis Tools
The software tools employed in this study included CiteSpace 6.4.R1, VOSviewer 1.6.19, Scimago Graphica 1.0.25, and WPS Excel 2023, complemented by the web platform Bioinformatics.com.cn (an online bioinformatics analysis and visualization cloud platform, http://www.bioinformatics.com.cn). CiteSpace was utilized for deduplication and organization of articles retrieved from WoS, with subsequent analyses encompassing co-occurrence networks, clustering networks, timeline mapping, and burst detection of references and keywords, followed by visualization. Parameter configurations were set as follows: time slicing (2015–2024, annual slices), threshold selection via the g-index (K=10), and network optimization using the Pathfinder algorithm to prune slice networks followed by secondary pruning after network merging. In visualized graphs, node diameters were proportional to frequency of occurrence, while link widths reflected co-occurrence strength. VOSviewer was applied to analyze and visualize collaborative networks of journals, cited journals, institutions, countries, authors, and cited authors within the paper corpus, with node diameters scaled to publication or citation counts and link widths indicating collaboration intensity. Scimago Graphica primarily facilitated country collaboration network visualization by importing GML-format country collaboration tables derived from VOSviewer, with parameters configured as: label=Country, cluster=String; node diameters mapped to national publication volumes, and link thickness determined by inter-country collaboration frequency. WPS Excel was employed for descriptive statistical analysis, generating bar charts and column graphs to represent diverse datasets.
Target Acquisition and Enrichment Analysis
The GeneCards database (https://www.genecards.org/) was searched using the keywords “rheumatoid arthritis” and “bone erosion” and targets with a Score ≥10 were screened and exported as disease-related targets.19,20 The intersection of targets obtained from “rheumatoid arthritis” and “bone erosion” was used for subsequent PPI and KEGG enrichment analyses. For the PPI analysis, the acquired targets were imported into the STRING database (https://cn.string-db.org/), with the species set to “Homo sapiens.” The following parameters were applied: minimum required interaction score = high confidence (0.700), and “hide disconnected nodes in the network” was selected.21,22 The resulting PPI network data were exported in TSV format and visualized using Cytoscape_v3.7.2 software (https://cytoscape.org/).23 Based on the R 4.4.2 platform (www.r-project.org/), the clusterProfiler 4.6.2 package was employed to perform KEGG pathway enrichment analysis on the intersecting genes.24,25 The Benjamini-Hochberg method was used to correct for multiple hypothesis testing, and significant pathways (FDR < 0.05) were screened. After excluding human disease-related pathways, a “gene-pathway” regulatory network was constructed and visualized using Cytoscape.
Results
Annual Trends in Publication Output and Citation Frequency
Over the past decade, a total of 1,502 articles have been published on RA and bone erosion, with their annual publication volume and citation counts from 2015 to 2024 illustrated in Figure 1. The number of publications demonstrated an upward trend from 2015 to 2021, followed by a sharp decline in 2022 (42 articles), with subsequent recovery observed in 2023 and 2024. Regarding citation frequency, a linear growth trend was evident between 2015 and 2021, while the growth rate exhibited a significant reduction during the 2022–2024 period.
|
Figure 1 Publication Output and Citation Frequency in Rheumatoid Arthritis and Bone Erosion Research (2015–2024). |
Country/Region-Specific Publication Output and Collaborative Networks
Scimago Graphica software was used to analyze countries/regions collaboration networks, identifying 5 distinct clusters (Figure 2A). The associations between countries were further illustrated by a chord diagram (Figure 2B). The proportion of publications contributed by the top 10 countries/regions ranked by total output was further visualized (Figure 2C). The number of articles, total citations, average citations, and Total Link Strength for the top 10 countries/regions ranked by total publication output are presented in Table 2.
|
Table 2 The Top 10 Countries/Regions by Total Publication Volume |
Research Institutions and Association Analysis
The collaborative networks among research institutions were clustered and visualized via VOSviewer (Figure 3A). The top 10 institutions ranked by research output volume include Leiden University (31), University of Leeds (31), University of Copenhagen (27), China Medical University (26), Peking University (25), Sun Yat-sen University (24), University Hospital Erlangen (24), Sichuan University (22), Shanghai University of Traditional Chinese Medicine (22), Shanghai Jiao Tong University (22) (Figure 3B). Further analysis of institutional citation metrics revealed that while Leiden University (Netherlands) and the University of Leeds (UK) both ranked first with 31 research outputs, Leiden University demonstrated significantly higher citation impact (1,764 citations) and collaboration network strength (link strength 33), underscoring its pivotal influence and robust international partnerships in this field. In addition, research institutions such as the University of Copenhagen (Denmark), China Medical University (China), and Peking University (China) have demonstrated significant research capabilities and potential for international collaboration (Figure 3C and Table 3).
|
Table 3 Ranking of the Top 10 Institutions by Publication Volume |
Distribution of Publications Across Journals
The top 10 journals by publication volume in RA and bone erosion research over the past decade, are comprehensively summarized in Table 4. The journal with the highest number of publications is Arthritis Research & Therapy (64), followed by Frontiers in immunology (47), Clinical rheumatology (43), Annals of the rheumatic diseases (40). It is noteworthy that although Annals of the Rheumatic Diseases has published only 40 articles in this research field, the journal holds a JCR Quartile Q1 ranking with an impressive impact factor of 20.3. The relevant articles exhibit an average citation count of 22.61 and a link strength of 258, underscoring its academic authority in RA and bone erosion research. This study employed VOSviewer software to conduct a visualization analysis of the association network among relevant journals (Figure 4).
|
Table 4 Top 10 Journals by Total Number of Publications |
|
Figure 4 Co-citation network of journals related to rheumatoid arthritis and bone erosion research. |
Author Collaboration Network and Scholarly Impact
This study utilized VOSviewer software to analyze the authors engaged in RA and bone erosion research over the past decade, as well as their collaboration networks and academic influence (Figure 5). A total of 834 authors participated in studies related to RA and bone erosion. Information on the top 10 authors by number of publications is presented in Table 5. The most prolific author is Schett, Georg, with 34 published studies, the highest citation counts of 1,436, and a collaboration strength of 114. The second-ranking author is Kleyer, Arnd, with 19 publications, 706 citations, and a collaboration strength of 92. In addition, authors such as Rech, Juergen; Simon, David; and Conaghan, Philip G. also demonstrated considerable academic influence.
|
Table 5 Top 10 Most Productive Authors in Rheumatoid Arthritis and Bone Erosion Research |
|
Figure 5 Author collaboration network in rheumatoid arthritis and bone erosion research. |
Keyword Co-Occurrence and Thematic Evolution Analysis
The keyword co-occurrence network and clustering analysis generated by VOSviewer identified 11 distinct keyword clusters (Figure 6A). A temporal mapping of keywords was performed using CiteSpace to reveal the composition and time distribution of each cluster (Figure 6B). In the analysis of burst keywords, the keywords that emerged in 2015 included wrist (9.26), joint inflammation (5.2). In 2016, new bursts appeared for joint damage (8.26), ankylosing spondylitis (6.38). Between 2017 and 2018, radiographic progression (7.56), joint destruction (5.86), bone marrow edema (6.5), quantitative computed tomography (6.48), cytokines (5.1), and early rheumatoid arthritis (4.64) showed significant activity. From 2019, ultrasonography (4.85) emerged. After 2020, keywords such as receptor (6.23), protein (5.8), reliability (5.23), and apoptosis (4.58) became prominent. Since 2021, burst keywords have included diagnosis (7.27), nanoparticles (9.57), delivery (7.38), mineral density (6.73), and proliferation (6.21) (Figure 6C).
According to keyword frequency and betweenness centrality statistics, rheumatoid arthritis was the most frequently mentioned keyword (1131 occurrences), representing the central theme in the literature on RA and bone erosion. In terms of centrality, synovitis and double blind were tied for the highest centrality value (1.13). Other keywords such as bone mineral density (0.92), structural damage (0.88), and necrosis factor alpha (0.74) also exhibited strong network influence (Table 6).
|
Table 6 Top 10 Keywords by Frequency and Top 10 Keywords by Centrality |
Analysis of Cited References and Knowledge Structure
High-frequency co-cited references located at the core of the co-citation network include Smolen JS (2016, 2018), Takeuchi T (2016, 2019), McInnes IB (2011), Colebatch AN (2013), Harre U (2012), and Schett G (2012), with dense interconnections (Figure 7A). The co-citation clustering analysis identified 13 clusters (Figure 7B). Citation burst analysis revealed that 20 references exhibited significant citation bursts during 2015-2024. The reference with the strongest burst was Schett G (2012) (23.85), occurring from 2015 to 2017. This was followed by Smolen JS (2018) (17.91, 2020-2024), McInnes IB (2011) (17.31, 2015-2016) and Aletaha D (2018) (13.55, 2021-2024). The citation bursts were primarily concentrated in two periods: 2015-2016 and 2019-2021. Several references, such as Guo QY (2018) and Smolen JS (2020), showed sustained citation bursts over the past three years (Figure 7C).
|
Figure 7 (A) Co-citation network of highly cited references from 2015 to 2024. (B) Cluster analysis of co-cited references revealing thematic research areas. (C) Top 20 references with the strongest citation bursts and their active periods (2015–2024).26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44 |
Co-Expressed Genes and Functional Enrichment Analysis
Through retrieval of the Genecard database, we identified 467 and 721 differentially expressed genes associated with RA and bone erosion, respectively, with 211 overlapping genes obtained via cross-analysis. Key targets were identified through PPI analysis of the overlapping genes (Figure 8A), and the top 20 of these targets were subsequently visualized using a bar chart (Figure 8B). KEGG pathway enrichment analysis of the overlapping genes identified 68 relevant signaling pathways. The top 15 enriched pathways were presented in a bubble plot (Figure 8C), and their associations with the targets were further visualized using Cytoscape software (Figure 8D).
Discussion
Bone erosion represents a core pathological mechanism in RA, wherein synovitis-derived inflammatory mediators drive osteoclast activation and pannus development, resulting in progressive and irreversible articular structural destruction with subsequent functional disability.45–47 Bone erosion can occur early in RA, with radiographic evidence appearing in 10% of patients within 8 weeks of disease onset and in up to 60% of patients within one year.48 Bone erosion is typically correlated with disease activity and joint functional deterioration, playing a critical role in predicting RA prognosis and monitoring treatment efficacy.49,50 Since the occurrence of bone erosion is closely linked to joint damage, halting its progression has become a critical objective in the treatment of RA.
At different stages of bone erosion development in RA, various medical disciplines exhibit distinct therapeutic characteristics, and multidisciplinary care plays a crucial role.51–54 Rheumatology serves as the leading discipline in the diagnosis and management of the disease, with rheumatology healthcare professionals involved in diagnosis, treatment, and prognostic care. Radiology is essential for assessing the severity of RA-related bone erosion damage. Rehabilitation medicine employs multiple therapies, such as functional exercise, thermotherapy, and electrotherapy, to restore function, prevent disability, and enable patients to return to normal life to the greatest extent possible. Comprehensive multidisciplinary treatment contributes to improving the prognosis of RA patients with bone erosion.55–57 Therefore, conducting a bibliometric analysis of RA and bone erosion can help reveal patterns of disease progression, treatment principles, and research trends from a multidisciplinary medical perspective.
Bibliometric analyses indicate that publications in the field of RA and bone erosion over the past decade have exhibited a trend of initial growth, followed by a decline and subsequent resurgence. The early increase in publication volume and citation frequency suggests rapid development in this research area, likely driven by advances in immunology and imaging technologies. The decline in publication output and citation growth in 2022 may be attributed to disruptions in clinical trials and the diversion of research resources to COVID-19 studies, consistent with findings from prior research.58 By 2023, publication numbers gradually recovered to near-previous levels, indicating a revival of interest in this field. At the national level, China ranked first in total publications, with a proportion that has steadily increased, underscoring its dominant position in this research domain. The United States ranked second, though its proportion has gradually declined, suggesting a relative weakening of its leadership in this area. Analysis of international collaboration networks revealed close cooperation among countries, with clustering analysis further demonstrating that these collaborations exhibit distinct regional characteristics.
At the institutional level, the top 10 contributing institutions were concentrated in Europe and China, with Leiden University (Netherlands) and the University of Leeds (UK) producing the highest number of research outputs. However, Leiden University’s higher citation counts and stronger total link strength indicate greater influence and international collaboration capabilities compared to the University of Leeds. Co-occurrence clustering analysis of institutions revealed that collaborations are predominantly regionally constrained, highlighting the need for stronger cross-regional and inter-institutional partnerships to overcome geographical barriers. The journal Arthritis Research & Therapy published the highest number of studies in this field, while Annals of the Rheumatic Diseases held greater academic authority in RA and bone erosion research. Among authors, Professor Georg Schett ranked first in publication volume, citation frequency, and collaboration strength, demonstrating exceptional academic influence and pioneering contributions to the study of bone erosion mechanisms.
Keyword clustering analysis identified research hotspots in three main areas: RA diagnostic techniques, bone erosion mechanisms, and therapeutic research. Keywords such as ultrasound, magnetic resonance imaging, and ultrasonography reflected the application of imaging technologies in assessing RA-related bone erosion. High-frequency ultrasound has become a cornerstone tool for early RA diagnosis, enabling simplified disease evaluation by detecting synovial thickening, blood flow signals, and bone erosion markers.59 Standardization of ultrasound protocols has facilitated its use in RA subtyping and treatment efficacy assessment.60–62 MRI, with its high soft-tissue resolution, can identify early bone marrow edema and joint structural damage, offering unique advantages in predicting bone erosion progression and informing prognosis.63,64 Keywords such as T cells, synovial fibroblasts, and mice reflected mechanistic and methodological research on bone erosion, including inflammation and immune regulation mechanisms, as well as animal model applications. T cell-mediated inflammatory responses drive bone erosion in RA by secreting cytokines such as IL-17 and RANKL, which activate osteoclasts and suppress osteoblast function. Aberrant proliferation and proinflammatory cytokine secretion by synovial fibroblasts promote pannus formation, leading to cartilage and bone destruction.65,66 The CIA mouse model is widely used to simulate RA-induced bone erosion, providing a platform for mechanistic studies and targeted therapy development.67 Keywords such as double blind and activation reflected research on therapeutic strategies and clinical trials for RA-related bone erosion. The emerging keyword timeline revealed a clear research trajectory: early studies (2015–2018) focused on disease symptoms and pathological manifestations, including joint inflammation and structural damage; mid-term studies (2018–2021) emphasized technological innovations, particularly diagnostic techniques and standardization; and recent studies (2020–2024) prioritized molecular mechanisms and precision medicine, exploring targeted biologic therapies.
Citation-based analysis demonstrated that highly cited literature in this field forms a tightly interconnected knowledge network, confirming its foundational role in RA bone erosion research. Clustering analysis further identified three major research themes: pathological mechanisms, diagnostic technologies, and treatment strategies, aligning with keyword clustering results. Temporally, citation burst themes evolved from mechanistic exploration to therapeutic translation, with novel treatments such as JAK inhibitors gaining prominence.
Genetic analysis of RA and bone erosion revealed substantial overlap in core genes and signaling pathways, synergistically driving disease progression. Overlapping genes frequently included inflammation-related molecules (TNF, IL6, IL1B, IL10, IFNG) and immune regulators (STAT3, TLR4, CCL2), further corroborating the central role of chronic inflammation and immune dysregulation in RA-related joint and bone damage. KEGG enrichment analysis showed that overlapping genes were significantly enriched in immune response and osteoclast differentiation. Cytokine-cytokine receptor interaction signaling pathway plays a pivotal role in the pathogenesis of RA. In RA, dysregulated cytokine networks involving TNF-α, IL-6, IL-1β, and IL-17 mediate chronic synovial inflammation, osteoclast activation, and joint destruction by binding to their respective receptors and activating downstream signaling pathways.68 The activation of key signaling pathways, including the TNF, Toll-like receptor, IL-17, NFκB, JAK-STAT, NOD-like receptor, and PI3K-Akt pathways, is closely associated with pro-inflammatory cytokines.69 These inflammatory responses further modulate T cell differentiation, thereby influencing Th17 cell differentiation, Th1/Th2 cell polarization, and T cell receptor signaling, which collectively exacerbate immune dysregulation. Additionally, the inflammatory microenvironment upregulates the Receptor Activator of Nuclear Factor-κB Ligand (RANKL), promoting osteoclast differentiation and ultimately exacerbating bone erosion in RA.70
Limitations
This study has several limitations in data sources and methodology: First, the literature search was confined to the WOS Collection, ensuring quality but potentially omitting emerging or regional studies from other platforms. Second, the analysis included only research articles and reviews, excluding conference papers, case reports, and technical documents, which may contain innovative findings or technical details. Additionally, the bibliometric framework emphasized quantitative metrics, with limited depth in qualitative dimensions such as theoretical model construction or clinical translation. Future studies should address these limitations by incorporating diverse data sources and methodologies to more comprehensively reveal the research dynamics and knowledge evolution in RA bone erosion.
Conclusion
Based on the WOS Collection, this study employed bibliometric methods to analyze RA and bone erosion research from 2015 to 2024 and systematically reviewed the research landscape, hotspots, and frontier trends. Bioinformatics analysis further elucidated shared targets and pathways between RA and bone erosion, offering insights to improve disease management and therapeutic strategies. The findings demonstrate growing global interest in this field over the past decade, with research focuses centered on RA diagnostic technologies, bone erosion mechanisms, and therapeutic research. Early studies emphasized disease symptoms and pathological manifestations, mid-term studies prioritized diagnostic technologies and standardization, and recent studies explored molecular mechanisms and precision medicine, including targeted biologic therapies. Bioinformatics analysis highlighted significant enrichment of immune response, infection-related, and bone metabolism pathways, suggesting their critical roles in RA-bone erosion comorbidity. This study provides a quantitative perspective on the evolution of RA bone erosion research, informing clinical decision-making and guiding future investigations through bioinformatics-driven insights.
Ethical Statement
According to article 32 of the “Measures for Ethical Review of Life Sciences and Medical Research Involving Humans” issued by Chinese government departments on February 18, 2023, ethical review may be exempted for life sciences and medical research involving humans that uses personal information data or biological samples under the following circumstances, provided that it causes no harm to human subjects, involves no sensitive personal information or commercial interests, thereby reducing unnecessary burdens on researchers and facilitating the conduct of such research. These circumstances include: (1) research utilizing legally obtained public data or data generated through observation without interference in public behaviors; (2) research conducted using anonymized information data. In this study, the retrieval and bibliometric analysis of relevant literature via the WOS database fulfill the above conditions, thus qualifying for an ethics exemption.
Funding
This study was supported by the National Natural Science Foundation of China (No. 82274435, 82074223).
Disclosure
The authors report no conflicts of interest in this work.
References
1. Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023;402(10416):2019–2033. doi:10.1016/S0140-6736(23)01525-8
2. Komatsu N, Takayanagi H. Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions. Nat Rev Rheumatol. 2022;18(7):415–429. doi:10.1038/s41584-022-00793-5
3. Terashima A, Ono K, Omata Y, Tanaka S, Saito T. Inflammatory diseases causing joint and bone destruction: rheumatoid arthritis and hemophilic arthropathy. J Bone Miner Metab. 2024;42(4):455–462. doi:10.1007/s00774-024-01520-8
4. Wang C, Zhang H, Wang X, Ma X, Zhang J, Zhang Y. Targeting BRD4 to attenuate RANKL-induced osteoclast activation and bone erosion in rheumatoid arthritis. Mol Cell Biochem. 2025;480(3):1669–1684. doi:10.1007/s11010-024-05073-2
5. Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the global burden of disease study 2017. Ann Rheum Dis. 2019;78(11):1463–1471. doi:10.1136/annrheumdis-2019-215920
6. Gu H, Yan D, Li J, Long X, Wang K. Trends and future projections of incidence rate and mortality of rheumatoid arthritis in China: a systematic analysis based on GBD 2021 data. Clin Rheumatol. 2024;43(9):2799–2806. doi:10.1007/s10067-024-07083-3
7. Li N, Jiang L, Cai Y, et al. The correlation between interleukin-34 and bone erosion under ultrasound in rheumatoid arthritis. Mod Rheumatol. 2020;30(2):269–275. doi:10.1080/14397595.2019.1593576
8. Marasco E, Fabbriciani G, Rotunno L, et al. Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion. Front Immunol. 2023;14:1254139. doi:10.3389/fimmu.2023.1254139
9. Yan L, Lin M, Ye X, et al. Prediction model for bone erosion in rheumatoid arthritis based on musculoskeletal ultrasound and clinical risk factors. Clin Rheumatol. 2025;44(1):143–152. doi:10.1007/s10067-024-07219-5
10. Joo YB, Park Y, Kim K, Bang SY, Bae SC, Lee HS. Association of CD8+ T-cells with bone erosion in patients with rheumatoid arthritis. Int J Rheum Dis. 2018;21(2):440–446. doi:10.1111/1756-185X.13090
11. Pascual-García S, Martínez-Peinado P, Pujalte-Satorre C, et al. Exosomal osteoclast-derived miRNA in rheumatoid arthritis: from their pathogenesis in bone erosion to new therapeutic approaches. Int J Mol Sci. 2024;25(3):1506. doi:10.3390/ijms25031506
12. Kachler K, Andreev D, Thapa S, et al. Acod1-mediated inhibition of aerobic glycolysis suppresses osteoclast differentiation and attenuates bone erosion in arthritis. Ann Rheum Dis. 2024;83(12):1691–1706. doi:10.1136/ard-2023-224774
13. Hu L, Liu R, Zhang L. Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors. Int Immunopharmacol. 2022;111:109095. doi:10.1016/j.intimp.2022.109095
14. Liu F, Chen F, Yang L, et al. Melittin acupoint injection in attenuating bone erosion in collagen-induced arthritis mice via inhibition of the RANKL/NF-κB signaling pathway. Quant Imaging Med Surg. 2023;13(9):5996–6013. doi:10.21037/qims-23-254
15. Tu AB, Lewis JS. Biomaterial-based immunotherapeutic strategies for rheumatoid arthritis. Drug Deliv Transl Res. 2021;11(6):2371–2393. doi:10.1007/s13346-021-01038-w
16. Zheng T, Pei Z, Huang X. Progress and frontiers of research on dexmedetomidine in perioperative medicine: a bibliometric analysis. Drug Des Devel Ther. 2024;18:6017–6029. doi:10.2147/DDDT.S471602
17. Liu M, Xiong Y, Zhang SH, Yuan J, Cheng ZQ. Integrating bibliometrics and bioinformatics to map knowledge structure, trends, and genetic insights in polycystic ovary syndrome and tumors (2015-2024). J Multidiscip Healthc. 2025;18:4675–4690. doi:10.2147/JMDH.S536122
18. Liu X, Wang N, Zhao T, Ran X, Chen G, Ma X. The application of acupuncture therapy for inflammatory arthropathies over the past decade: a bibliometric analysis. J Multidiscip Healthc. 2025;18:4833–4847. doi:10.2147/JMDH.S536199
19. Chen GY, Luo J, Liu Y, Yu XB, Liu XY, Tao QW. Network pharmacology analysis and experimental validation to investigate the mechanism of total flavonoids of rhizoma drynariae in treating rheumatoid arthritis. Drug Des Devel Ther. 2022;16:1743–1766. doi:10.2147/DDDT.S354946
20. Stelzer G, Rosen N, Plaschkes I, et al. The genecards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. 2016;54:1.30.1–1.30.33. doi:10.1002/cpbi.5
21. Chen GY, Liu XY, Yan XE, et al. Total flavonoids of rhizoma drynariae treat osteoarthritis by inhibiting arachidonic acid metabolites through AMPK/NFκB pathway. J Inflamm Res. 2023;16:4123–4140. doi:10.2147/JIR.S418345
22. Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638–D646. doi:10.1093/nar/gkac1000
23. Majeed A, Mukhtar S. Protein-protein interaction network exploration using cytoscape. Methods Mol Biol. 2023;2690:419–427.
24. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
25. Chen GY, Liu XY, Luo J, Yu XB, Liu Y, Tao QW. Integrating network pharmacology and experimental validation to explore the key mechanism of gubitong recipe in the treatment of osteoarthritis. Comput Math Methods Med. 2022;2022:7858925. doi:10.1155/2022/7858925
26. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012;8(11):656–664. doi:10.1038/nrrheum.2012.153
27. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. n Engl J Med. 2011;365(23):2205–2219. doi:10.1056/NEJMra1004965
28. Colebatch AN, Edwards CJ, Østergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72(6):804–814. doi:10.1136/annrheumdis-2012-203158
29. Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. j. Clin. Invest. 2012;122(5):1791–1802. doi:10.1172/JCI60975
30. Kleyer A, Finzel S, Rech J, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis. 2014;73(5):854–860. doi:10.1136/annrheumdis-2012-202958
31. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509. doi:10.1136/annrheumdis-2013-204573
32. Hecht C, Englbrecht M, Rech J, et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with ra. Ann Rheum Dis. 2015;74(12):2151–2156. doi:10.1136/annrheumdis-2014-205428
33. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. doi:10.1016/S0140-6736(16)30173-8
34. Barnabe C, Toepfer D, Marotte H, et al. Definition for rheumatoid arthritis erosions imaged with high resolution peripheral quantitative computed tomography and Interreader reliability for detection and measurement. J Rheumatol. 2016;43(10):1935–1940. doi:10.3899/jrheum.160648
35. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977. doi:10.1136/annrheumdis-2016-210715
36. Zayat AS, Ellegaard K, Conaghan PG, et al. The specificity of ultrasound-detected bone erosions for rheumatoid arthritis. Ann Rheum Dis. 2015;74(5):897–903. doi:10.1136/annrheumdis-2013-204864
37. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328–2337. doi:10.1016/S0140-6736(17)31472-1
38. Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. nat Rev Dis Primers. 2018;4:18001. doi:10.1038/nrdp.2018.1
39. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15. doi:10.1038/s41413-018-0016-9
40. Aletaha D, Smolen JS Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–1372. doi:10.1001/jama.2018.13103
41. Takeuchi T, Tanaka Y, Soen S, et al. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. Ann Rheum Dis. 2019;78(7):899–907. doi:10.1136/annrheumdis-2018-214827
42. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. doi:10.1136/annrheumdis-2019-216655
43. Burmester GR, Pope JE Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338–2348. doi:10.1016/S0140-6736(17)31491-5
44. Nygaard G, Firestein GS Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol. 2020;16(6):316–333. doi:10.1038/s41584-020-0413-5
45. Agemura T, Hasegawa T, Yari S, Kikuta J, Ishii M. Arthritis-associated osteoclastogenic macrophages (AtoMs) participate in pathological bone erosion in rheumatoid arthritis. Immunol Med. 2022;45(1):22–26. doi:10.1080/25785826.2021.1944547
46. Ostrowska M, Maśliński W, Prochorec-Sobieszek M, Nieciecki M, Sudoł-Szopińska I. Cartilage and bone damage in rheumatoid arthritis. Reumatologia. 2018;56(2):111–120. doi:10.5114/reum.2018.75523
47. Karmakar S, Kay J, Gravallese EM. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am. 2010;36(2):385–404. doi:10.1016/j.rdc.2010.03.003
48. Machold KP, Stamm TA, Nell VP, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology. 2007;46(2):342–349. doi:10.1093/rheumatology/kel237
49. Schneider AH, Taira TM, Públio GA, et al. Neutrophil extracellular traps mediate bone erosion in rheumatoid arthritis by enhancing RANKL-induced osteoclastogenesis. Br J Pharmacol. 2024;181(3):429–446. doi:10.1111/bph.16227
50. Fraenkel L, Bathon JM, England BR, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108–1123. doi:10.1002/art.41752
51. Walrabenstein W, Wagenaar CA, Van der leeden M, et al. A multidisciplinary lifestyle program for rheumatoid arthritis: the ‘Plants for Joints’ randomized controlled trial. Rheumatology. 2023;62(8):2683–2691. doi:10.1093/rheumatology/keac693
52. Corrao S, Calvo L, Giardina A, Cangemi I, Falcone F, Argano C. Rheumatoid arthritis, cardiometabolic comorbidities, and related conditions: need to take action. Front Med Lausanne. 2024;11:1421328. doi:10.3389/fmed.2024.1421328
53. Lahiri M, Cheung PPM, Dhanasekaran P, et al. Evaluation of a multidisciplinary care model to improve quality of life in rheumatoid arthritis: a randomised controlled trial. Qual Life Res. 2022;31(6):1749–1759. doi:10.1007/s11136-021-03029-3
54. Chen GY, Ji XY, Li Y, Zheng SS, Jin Q, Tao QW. Mechanisms of total glucosides of paeony in alleviating methotrexate-induced liver injury. Drug Des Devel Ther. 2025;19:3407–3423. doi:10.2147/DDDT.S521740
55. Sundin U, Sundlisater NP, Aga AB, et al. the ARCTIC Study Group. Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy. RMD Open. 2021;7(1):e001525. doi:10.1136/rmdopen-2020-001525
56. DI Matteo A, Emery P. Rheumatoid arthritis: a review of the key clinical features and ongoing challenges of the disease. Panminerva Med. 2024;66(4):427–442. doi:10.23736/S0031-0808.24.05272-8
57. Allameen NA, Lai YW, Lian G, et al. Physiotherapy and occupational therapy in rheumatoid arthritis: bridging functional and comorbidity gaps. Best Pract Res Clin Rheumatol. 2025;39(1):102032. doi:10.1016/j.berh.2024.102032
58. Zhao Y, Chen GY, Fang M. Research trends of rheumatoid arthritis and depression from 2019 to 2023: a bibliometric analysis. J Multidiscip Healthc. 2024;17:4465–4474. doi:10.2147/JMDH.S478748
59. Cipolletta E, Smerilli G, Di Matteo A, et al. The sonographic identification of cortical bone interruptions in rheumatoid arthritis: a morphological approach. Ther Adv Musculoskelet Dis. 2021;13:1759720X211004326. doi:10.1177/1759720X211004326
60. Zhu J, Qiu L, Ta D, et al. Chinese ultrasound doctors association guideline on operational standards for 2-D shear wave elastography examination of musculoskeletal tissues. Ultrasound Med Biol. 2024;50(2):175–183. doi:10.1016/j.ultrasmedbio.2023.10.005
61. Ogura T, Katagiri T, Kameda H. Cartilage evaluation by ultrasonography in patients with rheumatoid arthritis: a scoping review. Inflamm Regen. 2023;43(1):34. doi:10.1186/s41232-023-00286-2
62. Zufferey P, Tamborrini G, Gabay C, et al. Recommendations for the use of ultrasound in rheumatoid arthritis: literature review and SONAR score experience. Swiss Med Wkly. 2013;143(5152):w13861. doi:10.4414/smw.2013.13861
63. Bertham DP, Tan AL, Booth A, et al. Repeatability of quantitative MRI in patients with rheumatoid arthritis. Radiography. 2022;28(3):831–837. doi:10.1016/j.radi.2022.01.004
64. Wu S, Griffith JF, Xiao F, Yiu C, Leung JCS, Tam LS. Early rheumatoid arthritis, two distinctive structural damage patterns revealed by MRI: an 8-year longitudinal study. Eur Radiol. 2025;35(9):5403–5417. doi:10.1007/s00330-025-11493-5
65. Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021;22(1):10–18. doi:10.1038/s41590-020-00816-x
66. Chin A, Small A, Wong SW, Wechalekar MD. T cell dysregulation in rheumatoid arthritis: from genetic susceptibility to established disease. Curr Rheumatol Rep. 2025;27(1):14. doi:10.1007/s11926-025-01180-1
67. Miyoshi M, Liu S. Collagen-induced arthritis models. Methods Mol Biol. 2024;2766:3–7.
68. Kondo N, Kuroda T, Kobayashi D. Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci. 2021;22(20):10922. doi:10.3390/ijms222010922
69. Chen Z, Bozec A, Ramming A, Schett G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 2019;15(1):9–17. doi:10.1038/s41584-018-0109-2
70. Udagawa N, Koide M, Nakamura M, et al. Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab. 2021;39(1):19–26. doi:10.1007/s00774-020-01162-6
© 2025 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms
and incorporate the Creative Commons Attribution
- Non Commercial (unported, 4.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Recommended articles
Knowledge Mapping of Acupuncture for Fibromyalgia from 1990 to 2022: A Bibliometric Analysis
Li P, Zheng H, Chen Y, Liu Z, He J
Journal of Pain Research 2022, 15:2405-2426
Published Date: 18 August 2022
Research Hotspots and Trends on Acupuncture for Neuropathic Pain: A Bibliometric Analysis from 2002 to 2021
Liu D, Chen B, Li T, Zheng L, Li J, Du W, Wang M, Huang Y
Journal of Pain Research 2022, 15:3381-3397
Published Date: 25 October 2022
Knowledge Mapping of International Research on Acupuncture for Chronic Pain: A Bibliometric Analysis
Jiao H, Ding R, Jin P, Wang J, Xu J, Tian W
Journal of Pain Research 2022, 15:3711-3728
Published Date: 2 December 2022
Bibliometrics Analysis and Visualization of Sarcopenia Associated with Osteoporosis from 2000 to 2022
Yang J, Jiang T, Xu G, Liu W
Journal of Pain Research 2023, 16:821-837
Published Date: 13 March 2023
Global Trends and Performances of Acupuncture Therapy on Bell’s Palsy from 2000 to 2023: A Bibliometric Analysis
Yu G, Luo S, Zhu C, Chen L, Huang H, Nie B, Gu J, Liu J
Journal of Pain Research 2023, 16:2155-2169
Published Date: 26 June 2023
